Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences Inc (NQ: ENSC )

0.4961 -0.0029 (-0.58%)
Streaming Delayed Price Updated: 1:41 PM EDT, Jun 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 334,039
Open 0.5050
Bid (Size) 0.4925 (29)
Ask (Size) 0.4997 (57)
Prev. Close 0.4990
Today's Range 0.4911 - 0.5060
52wk Range 0.4000 - 17.12
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform
SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to... 
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting
- Shareholder Meeting to be Held on Thursday, June 23rd at 9:00 AM PT 
From Ensysce Biosciences, Inc.
Via AccessWire
Topics Death Intellectual Property
Exposures Death Intellectual Property

Performance

YTD
-88.44%
-88.44%
1 Month
-11.52%
-11.52%
3 Month
-54.06%
-54.06%
6 Month
-87.84%
-87.84%
1 Year
-96.58%
-96.58%

More News

Read More
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Via Benzinga
Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Releases 2021 Annual Shareholder Letter
From Ensysce Biosciences, Inc.
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Exposures Death Intellectual Property Legal
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
Via FinancialNewsMedia
Dr. Lynn Kirkpatrick, Invited Speaker at SMi 22nd Annual Pain Therapeutics Conference in London UK
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call
From Ensysce Biosciences, Inc.
Via AccessWire
51 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Earnings Scheduled For March 31, 2022
Via Benzinga
42 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
52 Biggest Movers From Yesterday
Via Benzinga
35 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
20 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
23 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.